# A Phase I Study of the Chimeric Anti-CD40 Monoclonal Antibody ChiLob 7/4 to Treat Advanced Malignancies Refractory to Conventional Anti-cancer Treatment

> **NCT01561911** · PHASE1 · COMPLETED · sponsor: **Cancer Research UK** · enrollment: 29 (actual)

## Conditions studied

- Cancer
- Neoplasms
- Lymphoma
- Non-Hodgkin
- B-Cell

## Interventions

- **DRUG:** Chi Lob 7/4 (A chimeric monoclonal antibody)

## Key facts

- **NCT ID:** NCT01561911
- **Lead sponsor:** Cancer Research UK
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2014-10
- **Final completion:** 2014-10
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2014-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01561911

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01561911, "A Phase I Study of the Chimeric Anti-CD40 Monoclonal Antibody ChiLob 7/4 to Treat Advanced Malignancies Refractory to Conventional Anti-cancer Treatment". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01561911. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*